These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 8352541)
1. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis. Koten JW; Neijt JP; Zonnenberg BA; Den Otter W Anticancer Res; 1993; 13(4):1179-82. PubMed ID: 8352541 [TBL] [Abstract][Full Text] [Related]
2. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. Karakosta A; Golias Ch; Charalabopoulos A; Peschos D; Batistatou A; Charalabopoulos K J Exp Clin Cancer Res; 2005 Dec; 24(4):505-14. PubMed ID: 16471312 [TBL] [Abstract][Full Text] [Related]
3. Carcinogen-induced impairment of enzymes for replicative fidelity of DNA and the initiation of tumours. Bignold LP Carcinogenesis; 2004 Mar; 25(3):299-307. PubMed ID: 14604890 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial tumour suppressors: a genetic and biochemical update. Gottlieb E; Tomlinson IP Nat Rev Cancer; 2005 Nov; 5(11):857-66. PubMed ID: 16327764 [TBL] [Abstract][Full Text] [Related]
5. Genetic pathways of two types of gastric cancer. Tahara E IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305 [TBL] [Abstract][Full Text] [Related]
6. A long view of fashions in cancer research. Harris H Bioessays; 2005 Aug; 27(8):833-8. PubMed ID: 16015588 [TBL] [Abstract][Full Text] [Related]
7. Oncogenesis by mutations in anti-oncogenes: a view. Den Otter W; Koten JW; Van der Vegt BJ; Beemer FA; Boxma OJ; Derkinderen DJ; De Graaf PW; Huber J; Lips CJ; Roholl PJ Anticancer Res; 1990; 10(2B):475-87. PubMed ID: 2190526 [TBL] [Abstract][Full Text] [Related]
8. The cell-type-specificity of inherited predispositions to tumours: review and hypothesis. Bignold LP Cancer Lett; 2004 Dec; 216(2):127-46. PubMed ID: 15533589 [TBL] [Abstract][Full Text] [Related]
9. The somatic mutation theory of cancer: growing problems with the paradigm? Soto AM; Sonnenschein C Bioessays; 2004 Oct; 26(10):1097-107. PubMed ID: 15382143 [TBL] [Abstract][Full Text] [Related]
11. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours. Tan Y; Sinniah R; Bay BH; Singh G J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489 [TBL] [Abstract][Full Text] [Related]
12. [Molecular mechanism of cancer seeding: adhesion molecules and signal transduction networks]. Mareel M; Vermeulen S; Bracke M Verh K Acad Geneeskd Belg; 1997; 59(4):327-51. PubMed ID: 9490922 [TBL] [Abstract][Full Text] [Related]
13. Information dynamics in carcinogenesis and tumor growth. Gatenby RA; Frieden BR Mutat Res; 2004 Dec; 568(2):259-73. PubMed ID: 15542113 [TBL] [Abstract][Full Text] [Related]
14. Lack of mutations within ST7 gene in tumour-derived cell lines and primary epithelial tumours. Brown VL; Proby CM; Barnes DM; Kelsell DP Br J Cancer; 2002 Jul; 87(2):208-11. PubMed ID: 12107844 [TBL] [Abstract][Full Text] [Related]
17. Aneuploidy, the somatic mutation that makes cancer a species of its own. Duesberg P; Rasnick D Cell Motil Cytoskeleton; 2000 Oct; 47(2):81-107. PubMed ID: 11013390 [TBL] [Abstract][Full Text] [Related]
18. Mutations and altered expression of the human cancer genes: what they tell us about causes. Devereux TR; Risinger JI; Barrett JC IARC Sci Publ; 1999; (146):19-42. PubMed ID: 10353382 [TBL] [Abstract][Full Text] [Related]
19. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Lincoln DT; Singal PK; Al-Banaw A Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic pathways in hereditary and sporadic breast cancer. Kenemans P; Verstraeten RA; Verheijen RH Maturitas; 2004 Sep; 49(1):34-43. PubMed ID: 15351094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]